You are here: Industry Insights > Market News > Vivimed Labs receives $ 7.5 million fund from OrbiMed Asia

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Gelatin, Soft Capsule Gelatin, Hard Capsule Gelatin, Pharmaceutical Gelatin-Foodmate

Neohesperidin

Advantame

Cleanroom Bench Horizontal Laminar Flow Hood Airflow Clean Bench

Pharma and Food Grade, USP/FCC Neotame Sweetener E961

Trilobatin

Vivimed Labs receives $ 7.5 million fund from OrbiMed Asia

expressbpdJanuary 02, 2018

Tag: Vivimed Labs , Healthcare

Favorites

The additional funds will be utilised to fuel growth opportunities

Vivimed Labs has received additional investment of $ 7.5 million (over Rs 47 crore) from healthcare investment firm OrbiMed Asia in its subsidiary Vivimed Labs (Mascarene).

The company had earlier received $ 42.5 million from OrbiMed Asia in September 2017, Vivimed Labs said in a BSE filing.

The overseas subsidiary is the holding entity of the company’s active pharmaceutical ingredient (API) business, it added.

This additional follow on investment by OrbiMed Asia reiterates the confidence of the investor in the Vivimed business model in the health care industry, Vivimed Labs MD Santosh Varalwar said.

"The additional funds will fuel its growth opportunities overall," he added.

Previous:Mylan-Biocon’s breast cancer biosimilar gets ANVISA nod

Next:Some of FDA’s Major Policy Goals For 2018

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Everest Medicines announced NMPA acceptance of NDA for VELSIPITY(R) (etrasimod) to treat moderately to severely active UC.

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

Vivimed Labs receives $ 7.5 million fund from OrbiMed Asia | Pharmasources.com

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

PRNewswireDecember 12, 2024

Core8 Group, an Australian leader in high-tech and biotech innovation, has unveiled plans to develop Vietnam's first AI x ESG Hospital, marking a significant milestone in healthcare transformation.

You may like
More>>

Pet Plastic Amber Solid Pill Bottle Healthcare Supplement Container Withscrew Cap 250ml

White PE HDPE PP Pet Plastic Amber Solid Pill Bottle Healthcare Supplement Container Withscrew Cap 2

Gas Flow Restrictors For Healthcare And Lifesciences

Nutritional Healthcare Supplement OEM private label Enzyme Juice Prices Fresh Noni Fruit Powder

Pet Plastic Amber Solid Pill Bottle Healthcare Supplement Container Withscrew Cap 150ml

Pet Plastic Amber Solid Pill Bottle Healthcare Supplement Container Withscrew Cap 50ml

1%-10% Withanolide Ashwagandha Extract for Healthcare Products

Pet Plastic Amber Solid Pill Bottle Healthcare Supplement Container Withscrew Cap 250ml

White PE HDPE PP Pet Plastic Amber Solid Pill Bottle Healthcare Supplement 200ml

White PE HDPE PP Pet Plastic Amber Solid Pill Bottle Healthcare Supplement Container Withscrew Cap 2

Vivimed Labs receives $ 7.5 million fund from OrbiMed Asia

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

You may likeMore>>

You may like
More>>